Capital Fund Management S.A. Acquires Shares of 17,315 Incyte Co. (NASDAQ:INCY)

Capital Fund Management S.A. acquired a new stake in shares of Incyte Co. (NASDAQ:INCYGet Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 17,315 shares of the biopharmaceutical company’s stock, valued at approximately $1,271,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of Incyte by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,825,719 shares of the biopharmaceutical company’s stock valued at $262,527,000 after purchasing an additional 199,662 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Incyte by 1.3% during the 4th quarter. Northern Trust Corp now owns 2,006,987 shares of the biopharmaceutical company’s stock valued at $147,313,000 after purchasing an additional 25,489 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Incyte by 32.6% during the 3rd quarter. Invesco Ltd. now owns 1,804,957 shares of the biopharmaceutical company’s stock valued at $124,145,000 after purchasing an additional 444,265 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Incyte by 4.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,574,430 shares of the biopharmaceutical company’s stock valued at $108,289,000 after acquiring an additional 60,977 shares during the last quarter. Finally, California Public Employees Retirement System lifted its holdings in shares of Incyte by 0.7% in the 3rd quarter. California Public Employees Retirement System now owns 1,444,432 shares of the biopharmaceutical company’s stock valued at $99,348,000 after acquiring an additional 10,093 shares during the last quarter. 92.78% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently commented on INCY shares. Zacks Investment Research raised shares of Incyte from a “sell” rating to a “hold” rating and set a $85.00 price target for the company in a report on Tuesday, April 5th. Stifel Nicolaus increased their price target on shares of Incyte from $75.00 to $77.00 in a report on Tuesday, May 3rd. TheStreet downgraded shares of Incyte from a “b” rating to a “c” rating in a report on Tuesday, May 3rd. Royal Bank of Canada raised shares of Incyte from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $78.00 to $90.00 in a research note on Tuesday, January 18th. Finally, SVB Leerink downgraded shares of Incyte from a “market perform” rating to an “underperform” rating and decreased their price objective for the stock from $60.00 to $56.00 in a research note on Wednesday, February 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $86.92.

In other Incyte news, Director Bros. Advisors Lp Baker acquired 99,800 shares of the business’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were bought at an average cost of $68.07 per share, with a total value of $6,793,386.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Barry P. Flannelly sold 43,993 shares of Incyte stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $83.49, for a total transaction of $3,672,975.57. Following the transaction, the executive vice president now directly owns 65,163 shares in the company, valued at $5,440,458.87. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 711,335 shares of company stock worth $49,689,821. 15.80% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:INCY opened at $74.51 on Tuesday. The firm has a market cap of $16.50 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 0.90 and a beta of 0.71. The firm’s 50 day simple moving average is $77.34 and its 200-day simple moving average is $72.53. Incyte Co. has a one year low of $61.91 and a one year high of $88.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.67 and a current ratio of 3.71.

Incyte (NASDAQ:INCYGet Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $733.20 million for the quarter, compared to analyst estimates of $753.54 million. Incyte had a net margin of 29.95% and a return on equity of 12.77%. The company’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same period last year, the company posted $0.50 earnings per share. Equities research analysts predict that Incyte Co. will post 2.31 EPS for the current fiscal year.

Incyte Profile (Get Rating)

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

See Also

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.